Cure My Disease

Don't miss your cure!

 Log in / Sign up

New glasses aim to balance unequal vision in nearsighted kids

NCT ID NCT07533149

Disease control Sponsor: Essilor International Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether special research glasses can reduce the difference in prescription between the two eyes in children aged 6 to 13 with myopic anisometropia (when one eye is much more nearsighted than the other). Twenty children will wear the study glasses and have their eye length and prescription measured over time. The goal is to see if the glasses can help control the condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 13 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Voluntary 2. Informed consent of parent/guardian and assent of participant 3. Age equal to or greater than 6 years old and less than 13 years at the time of signing informed consent and assent 4. SER equal or less than -0.50 D and equal or greater than .5.00 D with astigmatism not more than 2.50 D 5. Difference in SER (anisometropia) between two eyes .1.00 D 6. Best corrected visual acuity (BCVA) better than or equal to +0.20 LogMAR in each eye 7. Agree to wear study spectacles for .12 hours/day and 7 days/week 8. Willingness and ability to participate in investigation for 12 months and attend scheduled visits punctually 9. Agree for no concurrent involvement in other myopia control treatment Exclusion Criteria: 1. History or presence of an ocular disease affecting refractive status 2. History or presence of strabismus 3. Presence of amblyopia 4. Current or previous use of atropine and/or orthokeratology 5. Known allergy to cycloplegic agents 6. Contraindication to cycloplegic agents 7. Cognitive or psychological vulnerability

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anisometropia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anisometropia myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anisometropia Myopia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Essilor R&D Centre Singapore

    Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.